President and CEOOfficers of the CorporationBoard of TrusteesLeadership CouncilHistory
Managing DiabetesChildhood DiabetesNutritionExerciseOnline Diabetes ClassesDiscussion BoardsInfo for Healthcare ProfessionalsJoslin Clinical Guidelines50-Year Medalist Program
Adult ClinicPediatricsEye CareInfo for Healthcare Professionals
Directory of Joslin InvestigatorsDiabetes Research Center Alumni Connection
Media RelationsNews ReleasesInside JoslinSocial Media
Affiliated CentersPharma & DeviceCorporate EducationPublicationsProfessional EducationInternationalCommercialization and VenturesJoslin Institute for Technology Translation (JITT)
Give NowHigh Hopes FundWays to GivePlanned GivingEventsGet InvolvedCorporate & Foundation SupportOur DonorsDevelopment Team

Diabetes Innovation 2012

Day 1: Sunday, September 23 | Day 2: Monday, September 24 | Day 3: Tuesday, September 25


   Day 3: Tuesday, September 25, 2012
6:30 AM Networking Breakfast

7:30 Welcome: Partnership and Collaboration Announcements

7:45 KEYNOTE:
Centers for Medicare and Medicaid Innovation (CMMI) Challenge Update: News from the Front


  • Deliver better care at lower costs through continuous process improvement
  • Identify, validate and scale innovative models to provide all beneficiaries with a seamless care experience
  • Ensure patients receive the right care, at the right time, in the right setting—every time
   Moderator: Edward Horton, MD, Joslin Diabetes Center
   Jim Hester, PhD, Centers for Medicare and Medicaid Innovation (CMMI)


8:30 – 12:00 SPOTLIGHT
Clinical Technology Breakthroughs


   Moderator: Sachin H. Jain, MD, MBA, Merck

8:30   The Artificial Pancreas—A Holy Grail for Type 1 Diabetes?
  • Is this the next best thing to a diabetes cure?
  • What are the risks of an artificial pancreas if not properly designed?
   Henry Anhalt, DO, Animas Corporation

9:00 Surgical “Cures” For Diabetes?
  • Duodenal-jejunal bypass for type 2 diabetes sparks a metabolic change, causing blood sugar levels to drop and seeming to cure diabetes
  • What are the clinical and financial implications of this “cure”?
   Philip Schauer, MD, Cleveland Clinic
   David Cummings, MD, University of Washington

9:30 Break

9:45 Stopping Before You Start:
New Technologies for Risk Identification and Screening

  • How recent findings can improve diabetes risk prediction through metabolite levels
  • Identify those at highest risk of developing diabetes with new technologies to start preventive measures early
   Robert E. Gerszten, MD, Massachusetts General Hospital
   David VanAvermaete, VeraLight

10:15 Microchip-Based Implants for Managing Diabetes:
How, Why and What about Safety and Security?

  • Roll out microchip technology, benefits and considerations
  • Evaluate clinician and patient data needs
  • Discuss security challenges and possible approaches
   Robert Farra, MicroCHIPS
   Kevin Fu, PhD, UMASS; University of Michigan

10:45 The Quantified Self on Steroids:
Innovation in Devices, Pumps and Monitors

  • How effective is technology for diabetes management?
  • What is the future of technology in type 1 diabetes?
   Howard Wolpert, MD, Joslin Diabetes Center

11:15   Clinical Applications in Diabetes Population Health:
The Good, the Bad and the Ugly

  • Evaluate the impact of clinical diabetes applications on A1C and LDL testing rates and laboratory values
  • Is participation in diabetes population health programs associated with appropriate clinical control of A1C and LDL values?
  • Do members of all ages benefit from participation in diabetes population health programs?
  • Discuss future applications for diabetes in population health management from a joint venture
   Moderator: Martin J. Abrahamson, MD, FACP, Joslin Diabetes Center
   Terry Golash, MD, Aetna
   James L. Holly, MD, Southeastern Texas Medical Association (SETMA)
   Brandon Savage, MD, Caradigm


12:00 PM Challenge Grant Announcements and Private Funding Opportunities
  • Foster radical rethinking of diabetes control approaches and impact measures given the scale of the epidemic
  • Diabetes Innovation Challenge: Create a contest shaped by “public crowdsourcing” for the best innovations to help people living with diabetes
  • Challenge grants for patient engagement technologies
  • Innovation in philanthropy: Supporting pioneering projects that bring fresh thinking and unconventional approaches to bear on the mostpressing health and health care problems
  • More!
   Wil Yu, US Department of Health and Human Services (HHS)
   Patricia Doykos, Bristol-Myers Squibb Foundation
   Angela Moskow, Sanofi US
   Brian C. Quinn, PhD, Robert Wood Johnson Foundation


1:00   Next Steps, Follow-up Plans and Adjourn

   John L. Brooks III, Joslin Diabetes Center

Page last updated: December 07, 2016